Alembic Pharma receives USFDA Final Approval for Entacapone Tablets USP, 200 mg

Written by Medical Dialogues Bureau Published On 2022-01-06T15:27:44+05:30 | Updated On 6 Jan 2022 3:27 PM IST

Alembic Pharma receives USFDA Final Approval for Entacapone Tablets USP, 200 mg

Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Entacapone Tablets USP, 200 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Comtan Tablets, 200 mg, of Orion Corporation. Entacapone Tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose "wearing-off" in patients with Parkinson's disease.

Also Read:Alembic Pharma Doxycycline Hyclate Delayed-Release Tablets get USFDA okay

Entacapone Tablets USP, 200 mg have an estimated market size of US$ 10.5 million for twelve months ending September 2021 according to IQVIA.

Alembic has received year to date (YTD) 17 approvals (13 final approvals and 4 tentative approvals) and a cumulative total of 156 ANDA approvals (136 final approvals and 20 tentative approvals) from USFDA.

Also Read:FDA approves high-tech sound wave surgery for common Parkinson's symptoms

alembic pharmaalembic pharma newsUSFDAAbbreviated New Drug ApplicationParkinsonEntacapone Tablets

Medical Dialogues Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.